ALG-000184 + entecavir

ALG-000184 + entecavir is an investigational oral combination therapy for chronic hepatitis B virus (HBV) infection. **ALG-000184** is a small molecule, oral prodrug of a capsid assembly modulator (CAM-E, converted to ALG-001075 in the body), which interferes with HBV replication through two mechanisms: inhibition of pregenomic RNA encapsidation (blocking viral DNA and RNA production) and prevention of de novo covalently closed circular DNA (cccDNA) synthesis (reducing hepatitis B surface antigen, HBsAg)[1][2][5]. **Entecavir** is a nucleoside analog reverse transcriptase inhibitor approved for chronic HBV, and is typically used under the brand name Baraclude. In clinical trials, the combination (ALG-000184 + entecavir) in HBeAg-positive chronic HBV patients demonstrates superior reductions in HBV DNA, HBV RNA, and HBsAg compared to entecavir alone and is well-tolerated[1][4][5]. The combination is being evaluated for its potential to achieve a functional cure of HBV infection.

Brand names

Baraclude (for entecavir, but not the combination)

Other names

ALG-000184 and entecavirALG000184 and entecavirALG 000184 and entecavirALG-000184 plus entecavirALG000184 plus entecavirALG 000184 plus entecavir